Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 8/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CTRC | Q99895 | 1/20 | 0.35 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.35 |
| ▸ | F3 | P13726 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765579 | 0.86 | F3 (0.39) | CMA1NTRK1CASP1CTRCNTRK3 | |
| SCHEMBL30765886 | 0.86 | CASP1 (0.40) | CMA1NTRK1CASP1ELANEMAPK1 | |
| SCHEMBL30765543 | 0.84 | ELANE (0.39) | CMA1NTRK1CASP1ELANEMAPK1 | |
| SCHEMBL30765764 | 0.83 | CMA1 (0.40) | CMA1CTRC | |
| SCHEMBL30766049 | 0.82 | NTRK1 (0.43) | CMA1NTRK1CASP1ELANECTRC | |
| Hydrochloric Acid SCHEMBL30765434 | 0.82 | NTRK1 (0.43) | CMA1NTRK1CASP1ELANECTRC | |
| SCHEMBL31558568 | 0.82 | NTRK1 (0.45) | CMA1NTRK1CASP1ELANECTRC | |
| SCHEMBL30765987 | 0.82 | F2 (0.37) | CMA1NTRK1CASP1CTRCF3 | |
| SCHEMBL30765494 | 0.81 | F3 (0.34) | CMA1CASP1CTRCF3F2 | |
| SCHEMBL30765634 | 0.79 | CASP1 (0.42) | CMA1NTRK1CASP1ELANECTRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |